Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858632 · ClinicalTrials.gov registry record · Phase 4
Immune Spatial Features of Guselkumab Cutaneous Response
A Phase 4 study of Psoriasis of Scalp, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05858632 is a Phase 4 study of Psoriasis of Scalp that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05858632, a Phase 4 study of Psoriasis of Scalp, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05858632
The ClinicalTrials.gov registry entry for NCT05858632 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis of Scalp appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT05858632 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05858632 about?
NCT05858632 is a clinical study titled "Immune Spatial Features of Guselkumab Cutaneous Response". This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
What is the current status of trial NCT05858632?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2023-07-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05858632 study?
This clinical trial studies the following conditions: Psoriasis of Scalp.
What interventions are being tested in trial NCT05858632?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05858632?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858632 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.